Charles River Laboratories Intl. Stock Price, News & Analysis (NYSE:CRL)

$106.97 +1.34 (+1.27 %)
(As of 02/23/2018 10:14 AM ET)
Previous Close$105.63
Today's Range$106.32 - $106.97
52-Week Range$86.25 - $119.05
Volume19,560 shs
Average Volume446,449 shs
Market Capitalization$5.08 billion
P/E Ratio41.59
Dividend YieldN/A
Beta0.74

About Charles River Laboratories Intl. (NYSE:CRL)

Charles River Laboratories Intl. logoCharles River Laboratories International, Inc. is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development. The Company operates in three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). The RMS segment includes Research Models and Research Model Services. The DSA segment includes Discovery Services and Safety Assessment. The Manufacturing segment includes Microbial Solutions, Avian, Biologics and Contract Manufacturing. The Company also provides a suite of products and services to support the Company's clients' manufacturing activities.

Receive CRL News and Ratings via Email

Sign-up to receive the latest news and ratings for CRL and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryLife Sciences Tools & Services
SectorMedical
SymbolNYSE:CRL
CUSIP15986410
Phone781-222-6000

Debt

Debt-to-Equity Ratio1.06%
Current Ratio1.78%
Quick Ratio1.54%

Price-To-Earnings

Trailing P/E Ratio41.5867779007004
Forward P/E Ratio18.54
P/E Growth1.5

Sales & Book Value

Annual Sales$1.86 billion
Price / Sales2.73
Cash Flow$8.17 per share
Price / Cash13.10
Book Value$22.08 per share
Price / Book4.84

Profitability

Trailing EPS$2.54
Net Income$123.35 million
Net Margins6.64%
Return on Equity26.14%
Return on Assets9.09%

Miscellaneous

Employees11,800
Outstanding Shares47,430,000

Charles River Laboratories Intl. (NYSE:CRL) Frequently Asked Questions

What is Charles River Laboratories Intl.'s stock symbol?

Charles River Laboratories Intl. trades on the New York Stock Exchange (NYSE) under the ticker symbol "CRL."

How will Charles River Laboratories Intl.'s stock buyback program work?

Charles River Laboratories Intl. declared that its board has approved a share buyback program on Sunday, June 4th 2017, which permits the company to repurchase $150,000,000.00 in shares, according to EventVestor. This repurchase authorization permits the company to repurchase shares of its stock through open market purchases. Stock repurchase programs are typically a sign that the company's board believes its shares are undervalued.

How were Charles River Laboratories Intl.'s earnings last quarter?

Charles River Laboratories Intl. Inc (NYSE:CRL) issued its quarterly earnings data on Tuesday, February, 13th. The medical research company reported $1.40 EPS for the quarter, topping analysts' consensus estimates of $1.26 by $0.14. The medical research company earned $478.50 million during the quarter, compared to the consensus estimate of $475.02 million. Charles River Laboratories Intl. had a return on equity of 26.14% and a net margin of 6.64%. The firm's revenue was up 2.5% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.21 earnings per share. View Charles River Laboratories Intl.'s Earnings History.

When will Charles River Laboratories Intl. make its next earnings announcement?

Charles River Laboratories Intl. is scheduled to release their next quarterly earnings announcement on Tuesday, May, 8th 2018. View Earnings Estimates for Charles River Laboratories Intl..

Where is Charles River Laboratories Intl.'s stock going? Where will Charles River Laboratories Intl.'s stock price be in 2018?

11 equities research analysts have issued 1 year price targets for Charles River Laboratories Intl.'s stock. Their forecasts range from $104.00 to $130.00. On average, they anticipate Charles River Laboratories Intl.'s stock price to reach $117.09 in the next twelve months. View Analyst Ratings for Charles River Laboratories Intl..

Who are some of Charles River Laboratories Intl.'s key competitors?

Who are Charles River Laboratories Intl.'s key executives?

Charles River Laboratories Intl.'s management team includes the folowing people:

  • James C. Foster, Chairman of the Board, Chief Executive Officer (Age 67)
  • Davide A. Molho, President, Chief Operating Officer (Age 48)
  • David R. Smith, Chief Financial Officer, Corporate Executive Vice President (Age 51)
  • David P. Johst, Corporate Executive Vice President - Human Resources, Chief Administrative Officer, General Counsel (Age 55)
  • William D. Barbo, Corporate Executive Vice President and Chief Commercial Officer (Age 56)
  • Michael Gunnar Knell, Corporate Senior Vice President, Chief Accounting Officer (Age 40)
  • George M. Milne Jr., Ph.D., Lead Independent Director (Age 73)
  • Martin Mackay Ph.D., Director (Age 60)
  • Jean-Paul Mangeolle, Director (Age 53)
  • Robert J. Bertolini, Independent Director (Age 55)

Who owns Charles River Laboratories Intl. stock?

Charles River Laboratories Intl.'s stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (8.52%), William Blair Investment Management LLC (2.97%), Renaissance Technologies LLC (2.95%), Ariel Investments LLC (2.86%), Mackenzie Financial Corp (2.26%) and Goldman Sachs Group Inc. (2.14%). Company insiders that own Charles River Laboratories Intl. stock include Bradley Nixon Scharfe, C Richard Reese, David P Johst, David Ross Smith, Davide Molho, George M Milne Jr, George Massaro, James C Foster, Jason Wesley Scharfe, John J Crowley, Kevin Ma, Nancy Gillett, Online Communications Bdirect, Richard F Wallman, Robert J Bertolini, Stephen D Chubb and William D Barbo. View Institutional Ownership Trends for Charles River Laboratories Intl..

Who sold Charles River Laboratories Intl. stock? Who is selling Charles River Laboratories Intl. stock?

Charles River Laboratories Intl.'s stock was sold by a variety of institutional investors in the last quarter, including Ariel Investments LLC, Millennium Management LLC, OppenheimerFunds Inc., WINTON GROUP Ltd, Cookson Peirce & Co. Inc., Quantitative Investment Management LLC, Pembroke Management LTD and Two Sigma Advisers LP. Company insiders that have sold Charles River Laboratories Intl. company stock in the last year include Bradley Nixon Scharfe, C Richard Reese, David P Johst, David Ross Smith, Davide Molho, George Massaro, James C Foster, Jason Wesley Scharfe, Kevin Ma, Online Communications Bdirect, Robert J Bertolini, Stephen D Chubb and William D Barbo. View Insider Buying and Selling for Charles River Laboratories Intl..

Who bought Charles River Laboratories Intl. stock? Who is buying Charles River Laboratories Intl. stock?

Charles River Laboratories Intl.'s stock was bought by a variety of institutional investors in the last quarter, including William Blair Investment Management LLC, TimesSquare Capital Management LLC, APG Asset Management N.V., Arrowstreet Capital Limited Partnership, Carillon Tower Advisers Inc., Acadian Asset Management LLC, Wells Fargo & Company MN and Mackenzie Financial Corp. Company insiders that have bought Charles River Laboratories Intl. stock in the last two years include Bradley Nixon Scharfe and Jason Wesley Scharfe. View Insider Buying and Selling for Charles River Laboratories Intl..

How do I buy Charles River Laboratories Intl. stock?

Shares of Charles River Laboratories Intl. can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Charles River Laboratories Intl.'s stock price today?

One share of Charles River Laboratories Intl. stock can currently be purchased for approximately $106.97.

How big of a company is Charles River Laboratories Intl.?

Charles River Laboratories Intl. has a market capitalization of $5.08 billion and generates $1.86 billion in revenue each year. The medical research company earns $123.35 million in net income (profit) each year or $2.54 on an earnings per share basis. Charles River Laboratories Intl. employs 11,800 workers across the globe.

How can I contact Charles River Laboratories Intl.?

Charles River Laboratories Intl.'s mailing address is 251 BALLARDVALE STREET, WILMINGTON MA, 01887. The medical research company can be reached via phone at 781-222-6000 or via email at [email protected]


MarketBeat Community Rating for Charles River Laboratories Intl. (CRL)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  264 (Vote Outperform)
Underperform Votes:  319 (Vote Underperform)
Total Votes:  583
MarketBeat's community ratings are surveys of what our community members think about Charles River Laboratories Intl. and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Charles River Laboratories Intl. (NYSE:CRL) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyHoldBuyHold
Consensus Rating Score: 2.552.402.502.43
Ratings Breakdown: 0 Sell Rating(s)
5 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
6 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
5 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $117.09$113.80$106.65$96.93
Price Target Upside: 6.79% upside5.48% upside5.19% upside2.77% downside

Charles River Laboratories Intl. (NYSE:CRL) Consensus Price Target History

Price Target History for Charles River Laboratories Intl. (NYSE:CRL)

Charles River Laboratories Intl. (NYSE:CRL) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/16/2018BarclaysReiterated RatingHold$110.00LowView Rating Details
2/15/2018Credit Suisse GroupReiterated RatingHold$108.00LowView Rating Details
2/13/2018Royal Bank of CanadaSet Price TargetHold$116.00HighView Rating Details
2/14/2018JPMorgan Chase & Co.Boost Price TargetOverweight -> Overweight$110.00 -> $120.00MediumView Rating Details
2/14/2018SunTrust BanksUpgradeHold -> Buy$107.66 -> $125.00MediumView Rating Details
2/13/2018Robert W. BairdSet Price TargetBuy$123.00HighView Rating Details
1/18/2018Evercore ISIInitiated CoverageIn -> In-Line$117.00LowView Rating Details
12/13/2017ArgusInitiated CoverageBuy -> Buy$120.00MediumView Rating Details
11/10/2017Bank of AmericaLower Price TargetBuy$117.00 -> $115.00N/AView Rating Details
10/9/2017Jefferies GroupBoost Price TargetBuy$120.00 -> $130.00N/AView Rating Details
6/28/2017CitigroupReiterated RatingNeutral$91.00 -> $104.00LowView Rating Details
12/16/2016Goldman Sachs GroupUpgradeSell -> Neutral$75.00 -> $77.00N/AView Rating Details
5/22/2016KeyCorpReiterated RatingHold$77.00N/AView Rating Details
4/26/2016GabelliInitiated CoverageBuy$96.00N/AView Rating Details
(Data available from 2/23/2016 forward)

Earnings

Charles River Laboratories Intl. (NYSE:CRL) Earnings History and Estimates Chart

Earnings by Quarter for Charles River Laboratories Intl. (NYSE:CRL)

Charles River Laboratories Intl. (NYSE CRL) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/8/2018$1.27N/AView Earnings Details
2/13/2018Q4 2017$1.26$1.40$475.02 million$478.50 millionViewListenView Earnings Details
11/9/2017Q3 2017$1.22$1.30$458.93 million$464.23 millionViewN/AView Earnings Details
8/9/2017Q2 2017$1.22$1.29$458.25 million$469.13 millionViewListenView Earnings Details
5/10/2017Q1 2017$1.14$1.29$437.04 million$445.80 millionViewN/AView Earnings Details
2/14/2017Q416$1.11$1.21$441.64 million$466.80 millionViewListenView Earnings Details
11/2/2016Q316$1.13$1.18$291.20 million$425.70 millionViewListenView Earnings Details
8/3/2016Q216$1.10$1.20$425.05 million$434.10 millionViewListenView Earnings Details
5/4/2016Q116$0.90$0.98$354.92 million$354.90 millionViewListenView Earnings Details
2/10/2016Q415$0.94$1.00$349.20 million$353.90 millionViewListenView Earnings Details
11/4/2015Q315$0.94$1.03$340.09 million$349.50 millionViewListenView Earnings Details
7/30/2015Q215$0.97$0.96$338.30 million$339.60 millionViewListenView Earnings Details
4/29/2015Q115$0.82$0.79$324.00 million$320.40 millionViewListenView Earnings Details
2/10/2015Q414$0.71$0.81$318.73 million$329.50 millionViewListenView Earnings Details
10/29/2014Q314$0.80$0.86$326.70 million$327.60 millionViewListenView Earnings Details
8/6/2014Q214$0.82$0.97$327.96 million$341.18 millionViewListenView Earnings Details
4/30/2014Q114$0.74$0.82$302.08 million$299.40 millionViewListenView Earnings Details
2/12/2014Q413$0.68$0.73$289.56 million$289.20 millionViewListenView Earnings Details
10/30/2013Q313$0.70$0.79$290.28 million$292.10 millionViewListenView Earnings Details
7/31/2013Q2 2013$0.71$0.73$293.77 million$294.40 millionViewListenView Earnings Details
5/1/2013Q1 2013$0.71$0.69$294.53 million$291.20 millionViewListenView Earnings Details
2/13/2013Q4 2012$0.60$0.64$280.81 million$280.10 millionViewListenView Earnings Details
10/30/2012$0.62$0.65ViewN/AView Earnings Details
8/7/2012$0.66$0.75ViewN/AView Earnings Details
5/2/2012$0.65$0.70ViewN/AView Earnings Details
2/13/2012$0.56$0.69ViewN/AView Earnings Details
11/1/2011$0.58$0.57ViewN/AView Earnings Details
8/2/2011$0.60$0.70ViewN/AView Earnings Details
5/3/2011$0.55$0.61ViewN/AView Earnings Details
2/8/2011$0.50$0.60ViewN/AView Earnings Details
11/3/2010Q3 2010$0.49$0.45ViewN/AView Earnings Details
8/2/2010Q2 2010$0.50$0.49ViewN/AView Earnings Details
4/26/2010Q1 2010$0.47$0.45ViewN/AView Earnings Details
2/8/2010Q4 2009$0.43$0.49ViewN/AView Earnings Details
11/3/2009Q3 2009$0.60$0.65ViewN/AView Earnings Details
8/4/2009Q2 2009$0.58$0.66ViewN/AView Earnings Details
5/5/2009Q1 2009$0.53$0.58ViewN/AView Earnings Details
2/9/2009Q4 2008$0.55$0.59ViewN/AView Earnings Details
11/5/2008Q3 2008$0.74$0.76ViewN/AView Earnings Details
8/5/2008Q2 2008$0.73$0.79ViewN/AView Earnings Details
5/6/2008Q1 2008$0.68$0.72ViewN/AView Earnings Details
2/11/2008Q4 2007$0.64$0.65ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Charles River Laboratories Intl. (NYSE:CRL) Earnings Estimates

2018 EPS Consensus Estimate: $5.59
2019 EPS Consensus Estimate: $6.53
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20185$1.24$1.30$1.26
Q2 20185$1.40$1.52$1.44
Q3 20185$1.38$1.44$1.40
Q4 20184$1.44$1.55$1.49
Q1 20191$1.56$1.56$1.56
Q2 20191$1.67$1.67$1.67
Q3 20191$1.62$1.62$1.62
Q4 20191$1.68$1.68$1.68
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Charles River Laboratories Intl. (NYSE:CRL)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Charles River Laboratories Intl. (NYSE CRL) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 2.20%
Institutional Ownership Percentage: 99.03%
Insider Trades by Quarter for Charles River Laboratories Intl. (NYSE:CRL)
Institutional Ownership by Quarter for Charles River Laboratories Intl. (NYSE:CRL)

Charles River Laboratories Intl. (NYSE CRL) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/21/2018William D BarboInsiderSell2,320$108.08$250,745.6021,276View SEC Filing  
2/16/2018David Ross SmithInsiderSell3,639$109.07$396,905.7315,110View SEC Filing  
2/15/2018James C FosterChairmanSell46$107.50$4,945.00292,621View SEC Filing  
2/15/2018Stephen D ChubbDirectorSell2,872$108.70$312,186.4036,461View SEC Filing  
1/18/2018Online Communications BdirectDirectorSell131,000$0.29$37,990.00
1/2/2018David Ross SmithInsiderSell5,486$109.53$600,881.58View SEC Filing  
1/2/2018James C FosterChairmanSell4,967$109.44$543,588.48329,928View SEC Filing  
1/2/2018Robert J BertoliniDirectorSell3,609$110.22$397,783.98View SEC Filing  
12/12/2017Kevin MaDirectorSell40,384$0.41$16,557.44
12/6/2017C Richard ReeseDirectorSell10,227$102.40$1,047,244.8051,444View SEC Filing  
11/10/2017Bradley Nixon ScharfeInsiderSell1,000,000$0.27$270,000.00
10/30/2017Bradley Nixon ScharfeInsiderBuy2,500$0.25$625.00
10/25/2017Bradley Nixon ScharfeInsiderBuy3,000$0.27$810.00
10/19/2017Bradley Nixon ScharfeInsiderBuy2,000$0.29$580.00
10/17/2017Bradley Nixon ScharfeInsiderBuy3,000$0.29$870.00
10/5/2017Davide MolhoInsiderSell6,165$110.00$678,150.00View SEC Filing  
9/5/2017Davide MolhoInsiderSell5,982$107.55$643,364.1022,714View SEC Filing  
8/17/2017William D BarboInsiderSell4,000$99.91$399,640.0020,424View SEC Filing  
8/14/2017David Ross SmithInsiderSell2,552$67.10$171,239.2011,671View SEC Filing  
7/17/2017George MassaroDirectorSell3,830$100.81$386,102.3018,731View SEC Filing  
7/10/2017James C FosterChairmanSell9,516$98.92$941,322.72361,171View SEC Filing  
6/22/2017Davide MolhoInsiderSell10,948$100.00$1,094,800.0027,497View SEC Filing  
6/22/2017James C FosterChairmanSell43,154$100.00$4,315,400.00361,178View SEC Filing  
6/8/2017David Ross SmithInsiderSell945$95.00$89,775.0014,203View SEC Filing  
5/26/2017Davide MolhoInsiderSell10,976$92.84$1,019,011.8427,525View SEC Filing  
5/23/2017Jason Wesley ScharfeDirectorSell10,000$0.31$3,100.00
5/17/2017Jason Wesley ScharfeDirectorSell10,000$0.34$3,400.00
5/12/2017George MassaroDirectorSell1,130$88.30$99,779.0015,831View SEC Filing  
5/11/2017Jason Wesley ScharfeDirectorSell6,000$0.36$2,160.00
5/10/2017Jason Wesley ScharfeDirectorSell9,000$0.36$3,240.00
3/29/2017Jason Wesley ScharfeDirectorSell10,000$0.34$3,400.00
3/16/2017Davide MolhoInsiderSell11,717$90.00$1,054,530.0028,266View SEC Filing  
3/10/2017David P JohstInsiderSell34,593$89.06$3,080,852.58201,005View SEC Filing  
3/6/2017William D BarboInsiderSell1,900$87.90$167,010.0022,224View SEC Filing  
3/3/2017David Ross SmithEVPSell3,890$88.12$342,786.8017,085View SEC Filing  
3/1/2017Robert J BertoliniDirectorSell5,255$87.53$459,970.1532,140View SEC Filing  
2/28/2017James C FosterChairmanSell4,910$87.09$427,611.90381,730View SEC Filing  
2/22/2017James C FosterChairmanSell9,717$87.64$851,597.88388,294View SEC Filing  
2/22/2017Jason Wesley ScharfeDirectorBuy15,000$0.29$4,350.00
2/21/2017Jason Wesley ScharfeDirectorBuy10,000$0.30$3,000.00
2/17/2017Jason Wesley ScharfeDirectorBuy10,000$0.30$3,000.00
2/15/2017Jason Wesley ScharfeDirectorBuy4,500$0.30$1,350.00
1/30/2017David P JohstInsiderSell13,950$78.00$1,088,100.00174,696View SEC Filing  
12/2/2016Stephen D ChubbDirectorSell4,564$71.57$326,645.4830,849View SEC Filing  
11/28/2016C Richard ReeseDirectorSell4,539$71.93$326,490.2744,943View SEC Filing  
8/30/2016Davide MolhoInsiderSell7,877$84.10$662,455.70View SEC Filing  
8/5/2016James C FosterChairmanSell18,351$85.63$1,571,396.13383,283View SEC Filing  
7/29/2016Richard F WallmanDirectorSell7,740$88.00$681,120.0024,190View SEC Filing  
7/1/2016George MassaroDirectorSell3,740$83.09$310,756.6018,935View SEC Filing  
5/24/2016John J CrowleyCAOSell1,913$85.00$162,605.006,883View SEC Filing  
5/13/2016Richard F WallmanDirectorSell1,970$82.32$162,170.4017,690View SEC Filing  
5/10/2016Richard F WallmanDirectorSell11,990$84.00$1,007,160.0027,420View SEC Filing  
5/9/2016George MassaroDirectorSell985$82.17$80,937.4513,020View SEC Filing  
5/6/2016Richard F WallmanDirectorSell2,720$81.00$220,320.0015,430View SEC Filing  
4/6/2016Davide MolhoVPSell30,667$80.00$2,453,360.0079,008View SEC Filing  
3/2/2016Nancy GillettVPSell7,015$75.00$526,125.0023,809View SEC Filing  
2/29/2016Nancy GillettVPSell3,646$73.50$267,981.0021,953View SEC Filing  
2/25/2016David P JohstVPSell34,075$73.02$2,488,156.50189,023View SEC Filing  
2/24/2016James C FosterCEOSell3,873$70.40$272,659.20402,707View SEC Filing  
2/23/2016George M Milne JrDirectorSell10,440$73.02$762,328.8038,200View SEC Filing  
2/22/2016James C FosterCEOSell9,831$73.12$718,842.72402,964View SEC Filing  
2/12/2016C Richard ReeseDirectorSell4,228$71.48$302,217.4431,123View SEC Filing  
2/12/2016Nancy GillettVPSell6,750$71.90$485,325.0025,392View SEC Filing  
2/1/2016Stephen D ChubbDirectorSell2,000$74.76$149,520.0011,504View SEC Filing  
12/17/2015George MassaroDirectorSell7,740$80.00$619,200.0013,120View SEC Filing  
12/17/2015Thomas F. AckermaninsiderSell10,000$80.00$800,000.00100,635View SEC Filing  
11/19/2015Thomas F. AckermaninsiderSell10,000$75.00$750,000.00100,635View SEC Filing  
11/4/2015Thomas F. AckermaninsiderSell21,612$70.01$1,513,056.12100,635View SEC Filing  
11/2/2015Stephen D ChubbDirectorSell2,000$66.57$133,140.0013,504View SEC Filing  
8/17/2015Thomas F AckermanInsiderSell5,000$75.53$377,650.00View SEC Filing  
5/15/2015Thomas F AckermanCFOSell3,900$70.51$274,989.00View SEC Filing  
5/7/2015George MassaroDirectorSell1,360$70.21$95,485.60View SEC Filing  
3/3/2015Stephen D ChubbDirectorSell2,000$75.52$151,040.00View SEC Filing  
3/2/2015Deborah Turner KochevarDirectorSell2,600$76.59$199,134.00View SEC Filing  
3/2/2015James C FosterCEOSell2,036$76.93$156,629.48View SEC Filing  
3/2/2015Nancy GillettVPSell4,379$76.72$335,956.88View SEC Filing  
2/27/2015Nancy GillettVPSell2,772$76.95$213,305.40View SEC Filing  
2/25/2015James C FosterCEOSell4,621$75.96$351,011.16View SEC Filing  
2/25/2015Nancy GillettVPSell5,015$76.12$381,741.80View SEC Filing  
2/24/2015James C FosterCEOSell4,800$75.70$363,360.00View SEC Filing  
2/24/2015Jorg GellerVPSell12,061$76.17$918,686.37View SEC Filing  
2/23/2015James C FosterCEOSell8,423$76.56$644,864.88View SEC Filing  
2/23/2015Jorg GellerVPSell7,041$76.59$539,270.19View SEC Filing  
2/20/2015George M Milne JrDirectorSell6,000$75.87$455,220.00View SEC Filing  
2/19/2015James C FosterCEOSell9,671$75.00$725,325.00View SEC Filing  
2/18/2015Stephen D ChubbDirectorSell5,011$73.97$370,663.67View SEC Filing  
2/17/2015Jorg GellerVPSell14,430$73.54$1,061,182.20View SEC Filing  
2/17/2015Thomas F AckermanCFOSell4,400$73.50$323,400.00View SEC Filing  
2/13/2015Davide MolhoVPSell19,075$74.00$1,411,550.00View SEC Filing  
2/12/2015Jorg GellerVPSell8,458$73.68$623,185.44View SEC Filing  
1/26/2015Thomas F AckermanCFOSell10,000$70.00$700,000.00View SEC Filing  
1/8/2015David P JohstVPSell4,737$67.00$317,379.00View SEC Filing  
1/7/2015David P JohstVPSell26,100$65.00$1,696,500.00View SEC Filing  
12/1/2014Stephen D ChubbDirectorSell2,000$64.44$128,880.00View SEC Filing  
11/28/2014David P JohstVPSell6,982$65.34$456,203.88View SEC Filing  
11/17/2014Thomas F AckermanCFOSell10,000$63.70$637,000.00View SEC Filing  
11/14/2014Jorg GellerVPSell5,610$63.57$356,627.70View SEC Filing  
11/6/2014C Richard ReeseDirectorSell5,849$63.39$370,768.11View SEC Filing  
11/4/2014John J CrowleyCAOSell1,000$64.00$64,000.00View SEC Filing  
11/3/2014Davide MolhoVPSell16,402$64.54$1,058,585.08View SEC Filing  
11/3/2014George MassaroDirectorSell16,710$65.00$1,086,150.00View SEC Filing  
11/3/2014Thomas F AckermanCFOSell36,100$65.00$2,346,500.00View SEC Filing  
10/30/2014Nancy GillettVPSell1,069$65.00$69,485.00View SEC Filing  
10/28/2014David P JohstVPSell74,780$64.00$4,785,920.00View SEC Filing  
10/3/2014James C FosterCEOSell136,647$62.00$8,472,114.00View SEC Filing  
9/29/2014Thomas F AckermanCFOSell5,000$60.00$300,000.00View SEC Filing  
9/4/2014Davide MolhoVPSell4,900$61.34$300,566.00View SEC Filing  
9/2/2014Stephen D ChubbDirectorSell2,000$59.18$118,360.00View SEC Filing  
8/26/2014George MassaroDirectorSell10,440$60.00$626,400.00View SEC Filing  
8/18/2014Thomas F AckermanCFOSell23,156$59.25$1,371,993.00View SEC Filing  
8/12/2014Richard F WallmanDirectorSell3,240$58.20$188,568.00View SEC Filing  
6/2/2014Stephen D ChubbDirectorSell2,000$52.93$105,860.00View SEC Filing  
5/22/2014Deborah Turner KochevarDirectorSell3,100$53.30$165,230.0011,370View SEC Filing  
5/8/2014George MassaroDirectorSell1,620$52.70$85,374.0016,510View SEC Filing  
5/5/2014Thomas AckermanCFOSell5,430$50.76$275,626.80113,781View SEC Filing  
3/7/2014Nancy GillettVPSell10,110$58.36$590,019.6038,515View SEC Filing  
3/4/2014Nancy GillettVPSell13,650$58.98$805,077.0048,625View SEC Filing  
3/3/2014Stephen ChubbDirectorSell2,000$58.70$117,400.0023,645View SEC Filing  
2/28/2014Jorg GellerVPSell7,486$59.41$444,743.2655,722View SEC Filing  
2/27/2014Nancy GillettVPSell4,000$60.00$240,000.0043,162View SEC Filing  
2/25/2014Jorg GellerVPSell3,188$58.49$186,466.1250,235View SEC Filing  
2/20/2014Nancy GillettVPSell4,000$58.96$235,840.0050,510View SEC Filing  
2/19/2014Stephen ChubbDirectorSell5,198$58.35$303,303.3025,645View SEC Filing  
2/18/2014Thomas AckermanCFOSell14,000$58.05$812,700.00105,539View SEC Filing  
1/13/2014David JohstVPSell19,750$58.00$1,145,500.00141,799View SEC Filing  
1/7/2014George MassaroDirectorSell5,750$54.00$310,500.0015,410View SEC Filing  
12/20/2013Thomas AckermanCFOSell5,000$52.72$263,600.00107,689View SEC Filing  
12/4/2013Jorg GellerVPSell7,200$51.93$373,896.0054,192View SEC Filing  
12/2/2013Stephen ChubbDirectorSell2,000$51.92$103,840.0026,843View SEC Filing  
9/16/2013George MassaroDirectorSell5,958$47.38$282,290.0415,410View SEC Filing  
9/9/2013James C FosterCEOSell174,479$47.00$8,200,513.00View SEC Filing  
9/4/2013Thomas F AckermanCFOSell6,100$46.13$281,393.00View SEC Filing  
9/3/2013Stephen ChubbDirectorSell2,000$46.49$92,980.0028,843View SEC Filing  
8/29/2013James FosterCEOSell40,983$47.00$1,926,201.00366,580View SEC Filing  
8/22/2013Davide MolhoVPSell6,500$47.93$311,545.0040,892View SEC Filing  
8/20/2013Stephen ChubbDirectorSell4,000$47.46$189,840.0030,843View SEC Filing  
8/5/2013Jorg GellerVPSell3,025$46.38$140,299.5055,085View SEC Filing  
8/5/2013Richard WallmanDirectorSell1,500$45.95$68,925.0016,700View SEC Filing  
8/2/2013Davide MolhoVPSell4,100$45.89$188,149.0040,892View SEC Filing  
8/2/2013Deborah Turner KochevarDirectorSell4,447$46.02$204,650.9413,870View SEC Filing  
8/2/2013Thomas AckermanCFOSell26,250$46.03$1,208,287.50105,039View SEC Filing  
6/3/2013Thomas F AckermanCFOSell4,000$42.40$169,600.00View SEC Filing  
5/14/2013James C FosterCEOSell113,810$45.00$5,121,450.00View SEC Filing  
5/10/2013George MassaroDirectorSell2,020$44.09$89,061.80View SEC Filing  
3/13/2013David P JohstVPSell17,038$45.00$766,710.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Charles River Laboratories Intl. (NYSE CRL) News Headlines

Source:
DateHeadline
 Analysts Expect Charles River Laboratories Intl. Inc (CRL) Will Post Earnings of $1.25 Per Share Analysts Expect Charles River Laboratories Intl. Inc (CRL) Will Post Earnings of $1.25 Per Share
www.americanbankingnews.com - February 22 at 11:10 PM
William D. Barbo Sells 2,320 Shares of Charles River Laboratories Intl. Inc (CRL) StockWilliam D. Barbo Sells 2,320 Shares of Charles River Laboratories Intl. Inc (CRL) Stock
www.americanbankingnews.com - February 22 at 12:29 PM
Charles River Laboratories Announces New Tumor Model CompendiumCharles River Laboratories Announces New Tumor Model Compendium
finance.yahoo.com - February 21 at 9:02 AM
Charles River Laboratories Intl. Inc (CRL) Insider David Ross Smith Sells 3,639 SharesCharles River Laboratories Intl. Inc (CRL) Insider David Ross Smith Sells 3,639 Shares
www.americanbankingnews.com - February 20 at 3:30 PM
Charles River Laboratories Intl. (CRL) Stock Rating Upgraded by SunTrust BanksCharles River Laboratories Intl. (CRL) Stock Rating Upgraded by SunTrust Banks
www.americanbankingnews.com - February 18 at 6:54 AM
Charles River Laboratories Intl. (CRL) Given Hold Rating at Credit Suisse GroupCharles River Laboratories Intl. (CRL) Given Hold Rating at Credit Suisse Group
www.americanbankingnews.com - February 17 at 8:12 PM
Charles River Laboratories Intl. (CRL) Rating Lowered to C+ at TheStreetCharles River Laboratories Intl. (CRL) Rating Lowered to C+ at TheStreet
www.americanbankingnews.com - February 17 at 7:06 PM
Charles River Laboratories Intl.s (CRL) Hold Rating Reaffirmed at BarclaysCharles River Laboratories Intl.'s (CRL) Hold Rating Reaffirmed at Barclays
www.americanbankingnews.com - February 17 at 3:48 PM
Research Analysts Issue Forecasts for Charles River Laboratories Intl. Incs FY2019 Earnings (CRL)Research Analysts Issue Forecasts for Charles River Laboratories Intl. Inc's FY2019 Earnings (CRL)
www.americanbankingnews.com - February 16 at 3:34 PM
Gabelli Weighs in on Charles River Laboratories Intl. Incs FY2018 Earnings (CRL)Gabelli Weighs in on Charles River Laboratories Intl. Inc's FY2018 Earnings (CRL)
www.americanbankingnews.com - February 16 at 11:52 AM
Charles River Laboratories Intl. Inc (CRL) Director Sells $312,186.40 in StockCharles River Laboratories Intl. Inc (CRL) Director Sells $312,186.40 in Stock
www.americanbankingnews.com - February 16 at 9:20 AM
Charles River Laboratories Intl. Inc (CRL) Expected to Post Q2 2018 Earnings of $1.52 Per ShareCharles River Laboratories Intl. Inc (CRL) Expected to Post Q2 2018 Earnings of $1.52 Per Share
www.americanbankingnews.com - February 16 at 8:52 AM
Market Trends Toward New Normal in Tile Shop Holdings, Cytokinetics, Limelight Networks, CatchMark Timber Trust, Global Payments, and Charles River Laboratories International — Emerging Consolidated Expectations, Analyst RatingsMarket Trends Toward New Normal in Tile Shop Holdings, Cytokinetics, Limelight Networks, CatchMark Timber Trust, Global Payments, and Charles River Laboratories International — Emerging Consolidated Expectations, Analyst Ratings
finance.yahoo.com - February 16 at 8:50 AM
Charles River Laboratories Intl. Inc (CRL) to Post FY2022 Earnings of $8.40 Per Share, Gabelli ForecastsCharles River Laboratories Intl. Inc (CRL) to Post FY2022 Earnings of $8.40 Per Share, Gabelli Forecasts
www.americanbankingnews.com - February 15 at 4:28 PM
William Blair Weighs in on Charles River Laboratories Intl. Incs Q1 2018 Earnings (CRL)William Blair Weighs in on Charles River Laboratories Intl. Inc's Q1 2018 Earnings (CRL)
www.americanbankingnews.com - February 15 at 8:48 AM
SunTrust Banks Weighs in on Charles River Laboratories Intl. Incs Q1 2018 Earnings (CRL)SunTrust Banks Weighs in on Charles River Laboratories Intl. Inc's Q1 2018 Earnings (CRL)
www.americanbankingnews.com - February 15 at 8:48 AM
Charles River Laboratories Intl. Inc to Post Q1 2018 Earnings of $1.24 Per Share, KeyCorp Forecasts (CRL)Charles River Laboratories Intl. Inc to Post Q1 2018 Earnings of $1.24 Per Share, KeyCorp Forecasts (CRL)
www.americanbankingnews.com - February 15 at 8:48 AM
Wired News – Charles River Labs Inked an Agreement to Acquire MPI ResearchWired News – Charles River Labs Inked an Agreement to Acquire MPI Research
finance.yahoo.com - February 15 at 8:27 AM
Charles River Laboratories Intl. (CRL) Price Target Raised to $120.00 at JPMorgan Chase & Co.Charles River Laboratories Intl. (CRL) Price Target Raised to $120.00 at JPMorgan Chase & Co.
www.americanbankingnews.com - February 14 at 7:46 PM
Charles River Laboratories (CRL) to Acquire MPI Research for $800 MillionCharles River Laboratories (CRL) to Acquire MPI Research for $800 Million
www.streetinsider.com - February 14 at 5:03 PM
Charles River Laboratories International, Inc. 2017 Q4 - Results - Earnings Call SlidesCharles River Laboratories International, Inc. 2017 Q4 - Results - Earnings Call Slides
seekingalpha.com - February 14 at 5:03 PM
Charles River Laboratories Intl. (CRL) Given a $116.00 Price Target at Royal Bank of CanadaCharles River Laboratories Intl. (CRL) Given a $116.00 Price Target at Royal Bank of Canada
www.americanbankingnews.com - February 14 at 12:32 PM
Charles River Laboratories Intl, Inc. -- Moodys affirms Charles Rivers Ba2 CFR; outlook stableCharles River Laboratories Int'l, Inc. -- Moody's affirms Charles River's Ba2 CFR; outlook stable
finance.yahoo.com - February 14 at 9:27 AM
Charles River Laboratories Intl.s (CRL) "Buy" Rating Reaffirmed at Robert W. BairdCharles River Laboratories Intl.'s (CRL) "Buy" Rating Reaffirmed at Robert W. Baird
www.americanbankingnews.com - February 13 at 8:08 PM
Charles River Labs to acquire contract research firm for $800MCharles River Labs to acquire contract research firm for $800M
finance.yahoo.com - February 13 at 4:09 PM
Charles River Laboratories to Acquire MPI ResearchCharles River Laboratories to Acquire MPI Research
finance.yahoo.com - February 13 at 9:32 AM
Charles River reports 4Q lossCharles River reports 4Q loss
finance.yahoo.com - February 13 at 9:32 AM
Charles River Laboratories Announces Executive Management AppointmentsCharles River Laboratories Announces Executive Management Appointments
finance.yahoo.com - February 13 at 9:32 AM
Charles River Laboratories Intl. Inc (CRL) Given Average Recommendation of "Hold" by BrokeragesCharles River Laboratories Intl. Inc (CRL) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - February 13 at 9:22 AM
Charles River Laboratories Intl. (CRL) Announces  Earnings ResultsCharles River Laboratories Intl. (CRL) Announces Earnings Results
www.americanbankingnews.com - February 13 at 8:54 AM
Should You Buy Charles River Laboratories (CRL) Ahead of Earnings?Should You Buy Charles River Laboratories (CRL) Ahead of Earnings?
finance.yahoo.com - February 9 at 4:44 PM
Zacks: Brokerages Anticipate Charles River Laboratories Intl. Inc (CRL) Will Announce Quarterly Sales of $476.73 MillionZacks: Brokerages Anticipate Charles River Laboratories Intl. Inc (CRL) Will Announce Quarterly Sales of $476.73 Million
www.americanbankingnews.com - February 7 at 1:44 AM
Charles River Laboratories Intl. Inc (CRL) Expected to Announce Earnings of $1.26 Per ShareCharles River Laboratories Intl. Inc (CRL) Expected to Announce Earnings of $1.26 Per Share
www.americanbankingnews.com - February 5 at 11:14 PM
Charles River Laboratories Intl. (CRL) Scheduled to Post Earnings on MondayCharles River Laboratories Intl. (CRL) Scheduled to Post Earnings on Monday
www.americanbankingnews.com - February 5 at 3:26 AM
Head-To-Head Comparison: Oncobiologics (ONS) vs. Charles River Laboratories Intl. (CRL)Head-To-Head Comparison: Oncobiologics (ONS) vs. Charles River Laboratories Intl. (CRL)
www.americanbankingnews.com - January 29 at 11:20 AM
Charles River Laboratories Schedules Fourth-Quarter 2017 Earnings and 2018 Guidance Release and Conference CallCharles River Laboratories Schedules Fourth-Quarter 2017 Earnings and 2018 Guidance Release and Conference Call
finance.yahoo.com - January 26 at 9:35 AM
FY2018 EPS Estimates for Charles River Laboratories Intl. Inc Cut by Analyst (CRL)FY2018 EPS Estimates for Charles River Laboratories Intl. Inc Cut by Analyst (CRL)
www.americanbankingnews.com - January 23 at 4:08 PM
Zacks: Analysts Expect Charles River Laboratories Intl. Inc (CRL) Will Announce Quarterly Sales of $476.43 MillionZacks: Analysts Expect Charles River Laboratories Intl. Inc (CRL) Will Announce Quarterly Sales of $476.43 Million
www.americanbankingnews.com - January 22 at 2:20 PM
Head-To-Head Contrast: GTX (GTXI) & Charles River Laboratories Intl. (CRL)Head-To-Head Contrast: GTX (GTXI) & Charles River Laboratories Intl. (CRL)
www.americanbankingnews.com - January 22 at 8:26 AM
$1.26 EPS Expected for Charles River Laboratories Intl. Inc (CRL) This Quarter$1.26 EPS Expected for Charles River Laboratories Intl. Inc (CRL) This Quarter
www.americanbankingnews.com - January 20 at 3:16 AM
Charles River Laboratories Intl. Inc (CRL) Director Sells $37,990.00 in StockCharles River Laboratories Intl. Inc (CRL) Director Sells $37,990.00 in Stock
www.americanbankingnews.com - January 19 at 4:26 PM
Charles River Laboratories Intl. Inc (CRL) Receives Average Rating of "Buy" from BrokeragesCharles River Laboratories Intl. Inc (CRL) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - January 19 at 10:02 AM
Evercore ISI Initiates Coverage on Charles River Laboratories Intl. (CRL)Evercore ISI Initiates Coverage on Charles River Laboratories Intl. (CRL)
www.americanbankingnews.com - January 18 at 5:28 PM
IIROC Trade Resumption - CRL, CRL.WT, CRL.RTIIROC Trade Resumption - CRL, CRL.WT, CRL.RT
finance.yahoo.com - January 17 at 5:38 PM
IIROC Trading Halt - CRL CRL.WT CRL.RTIIROC Trading Halt - CRL CRL.WT CRL.RT
finance.yahoo.com - January 17 at 5:38 PM
Charles River Laboratories (CRL) Appoints Jean-Paul Mangeolle to BoardCharles River Laboratories (CRL) Appoints Jean-Paul Mangeolle to Board
www.streetinsider.com - January 17 at 9:06 AM
Charles River Laboratories Adds Jean-Paul Mangeolle to Board of DirectorsCharles River Laboratories Adds Jean-Paul Mangeolle to Board of Directors
finance.yahoo.com - January 16 at 9:23 AM
Charles River Laboratories Acquires KWS BioTestCharles River Laboratories Acquires KWS BioTest
finance.yahoo.com - January 11 at 9:35 AM
BRIEF-Charles River Laboratories Says New Tax Legislation Expected To Be Effectively Neutral To Cos GAAP, Non-GAAP EPS In 2018BRIEF-Charles River Laboratories Says New Tax Legislation Expected To Be Effectively Neutral To Co's GAAP, Non-GAAP EPS In 2018
www.reuters.com - January 9 at 5:37 PM
Carl Data Solutions Announces Completion of Rights OfferingCarl Data Solutions Announces Completion of Rights Offering
finance.yahoo.com - January 8 at 5:39 PM

SEC Filings

Charles River Laboratories Intl. (NYSE:CRL) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Charles River Laboratories Intl. (NYSE:CRL) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Charles River Laboratories Intl. (NYSE CRL) Stock Chart for Friday, February, 23, 2018

Loading chart…

This page was last updated on 2/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.